Hosted on MSN19h
Breakthrough sickle cell drug causes excitementA groundbreaking sickle cell disease treatment has been approved for use in the UK's National Health Service (NHS). The treatment offers patients with severe forms of the condition hope for a ...
On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product.
Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.
IPC Indice de Precios Y Cotizaciones 51,889.75 680.22 1.33% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback